Business
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
--News Direct--By Ernest Dela Aglanu, BenzingaHouston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"--News Direct--By Ernest Dela Aglanu, BenzingaHouston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and commercialization of COYA 301 — the company’s low-dose IL-2 subcutaneous administration product candidate.For industry watchers, including investors, this might be very important, especially as multiple autoimmune diseases have largely unmet medical needs. A deep dive into the statistics by the American Autoimmune Related Diseases Association (AARDA) shows that an estimated ~50 million Americans have one or more autoimmune diseases.More worryingly, AARDA further said approximately 75% of those affected are women and tend to cluster in families, impacting multiple family members and generations. Autoimmune diseases are among the top 10 leading causes of death among American women.Expansion Of Its Exclusive Worldwide RightsThe statistics around autoimmune diseases are certainly worrying. To help make a difference, players like Coya are actively ramping up and expanding their therapies to address the needs of the market.Coya just announced the expansion of their exclusive worldwide rights with ARScience Biotherapeutics Inc. for the development and commercialization of COYA 301, Coya’s low-dose IL-2 subcutaneous administration product candidate.Since 2020, the clinical-stage biotechnology company has been developing multiple therapeutic platforms to enhance T cell (Treg) function, including biologics and cell therapies.COYA 301 is an immunomodulatory cytokine for subcutaneous administration intended to enhance regulatory Treg function in vivo to treat the systemic and neuro-inflammation underlying certain autoimmune and neurodegenerative diseases. Under the expanded terms of the agreement with ARScience, Coya reports that it has been granted the rights to develop and commercialize COYA as a combination therapy across multiple therapeutic areas and disease conditions and as a monotherapy for various neurodegenerative disorders and autoimmune diseases.The company expatiated that these additional rights expand on the rights provided in the original license, which allowed Coya to develop an...